A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI).

Trial Profile

A Randomized, Double-Blind, Multi-Center Phase II Trial of Exemestane (Aromasin) Plus Dasatinib Versus Exemestane Plus Placebo in Advanced Estrogen Receptor-Positive Breast Cancer After Disease Progression on a Non-Steroidal Aromatase Inhibitor (NSAI).

Completed
Phase of Trial: Phase II

Latest Information Update: 27 May 2014

At a glance

  • Drugs Dasatinib (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Jul 2012 Actual patient number changed from 156 to 157 as reported by ClinicalTrials.gov.
    • 18 Jul 2012 Actual end date (Jun 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top